|
|
225 Promenade du Centropolis Suite 210
Laval, Quebec H7T 0B3 Canada
phone:450.686.4555
fax:
|
|
| Symbol |
TSXV |
| Exchange |
APO.V |
| Founded |
2008 |
| Employees |
7 |
|
|
| www.acastipharma.com
|
|
|
|
 |
| Summary Description |
| Developing pharmaceutical and medical applications for Neptune Krill Oil |
|
| Management |
|
| |
|
|
|
|
|
|
|
| Keywords |
| omega-3, Neptune Krill Oil, cardiovascular |
|
|
|
| Description |
|
Acasti Pharma is advancing a portfolio of proprietary, novel omega-3 phospholipids for safe and effective pharmaceutical and medical applications, with an initial focus on cardiovascular disease. Phospholipids serve as the major component of cell membranes, are essential for all vital cell processes, and play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are stabilized by potent antioxidants; evidence has demonstrated the anti-inflammatory properties of EPA and DHA in regulating important biological functions related to degenerative, arthritic, circulatory, digestive, and brain diseases. Delivering omega-3s functionalized on phospholipids helps optimize the omega-3 fatty acid therapeutic benefits, while potent antioxidants contribute to proper physiological regulation that prevents free radical cellular damage, a common pathway to cardiovascular disease and inflammation as well as neurodegenerative disease. This earlier-stage specialty pharmaceuticals company is currently in pharmaceutical negotiations regarding medical foods, over-the-counter products, and prescription drugs that it is developing with its phospholipids technologies. |
|
| Products / Services |
Acasti's proprietary product portfolio for the management of cardiometabolic disorders, from prevention to treatment. Acasti is the maker of first-in-class and best-in-class anti-dyslipidemic prescription drugs, CaPreT, medical food, OnemiaT and over-the-counter (OTC) product, VectosT. Acasti's lead product, CaPreT, intended for use in the treatment of dyslipidemia is currently tested in two phase II clinical trial in Canada and has demonstrated a superior efficacy and safety profile than other existing treatment in established preclinical models.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members